Notably, this antitumor effect depends on IFN-γ, as IFN-γ-deficient subjects did not show significant immune responses, and treatment showed minimal side effects, highlighting OMVs as a promising cancer therapy [23]. This evidence concerns the gene IFNG and cancer.